EUCTR2008-004642-92-HU进行中（未招募）不适用
Evaluation of efficacy and clinical benefit of agomelatine (25 to 50 mg/day) over a 6-month treatment period in patients with Major Depressive Disorder.A randomised, double-blind, international multicentre study with parallel groups versus duloxetine (60 mg/day).Twenty-four weeks of treatment.
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 400
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Out-patients of both genders - Aged between 18 (or minimum legal age) and 65 years (inclusive) - fulfilling DSM-IV criteria for Major Depressive Disorder.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Women of childbearing potential without effective contraception, - Other types of depression than MDD, - Any clinically relevant abnormality detected during the physical examination, ECG or laboratory tests likely to interfere with the study conduct or evaluations.
研究者
相似试验
进行中（未招募）
不适用
Evaluation of efficacy and clinical benefit of agomelatine (25 to 50 mg/day) over a 6-month treatment period in patients with Major Depressive Disorder. A randomised, double blind, international multicentre study with parallel groups versus duloxetine (60 mg/day). Twenty-four weeks of treatment. - NDMedDRA version: 9.1Level: LLTClassification code 10057840Term: Major depressionMajor Depressive DisorderEUCTR2008-004642-92-ITINSTITUT DE RECHERCHES INTERNATIONALES SERVIER400
进行中（未招募）
不适用
Evaluation of efficacy and clinical benefit of agomelatine (25 to 50 mg/day) over a 6-month treatment period in patients with Major Depressive Disorder.A randomised, double-blind, international multicentre study with parallel groups versus duloxetine (60 mg/day).Twenty-four weeks of treatment.Major Depressive DisorderEUCTR2008-004642-92-PTInstitut de Recherches Internationales Servier400
进行中（未招募）
不适用
Evaluation of efficacy and clinical benefit of agomelatine (25 to 50 mg/day) over a 6-month treatment period in patients with Major Depressive Disorder.A randomised, double-blind, international multicentre study with parallel groups versus duloxetine (60 mg/day).Twenty-four weeks of treatment.Major Depressive DisorderEUCTR2008-004642-92-GBInstitut de Recherches Internationales Servier400
已完成
3 期
Evaluation of efficacy and clinical benefit of agomelatine in patients with major depressive disorder compared to serotonin-norepinephrine reuptake inhibitor (SNRI)Major depressive disorderMental and Behavioural DisordersDepressive episodeISRCTN96725312Institut de Recherches Internationales Servier (France)418
尚未招募
2 期
The study of the effect of amaltas with jaggery in constipation in pregnancyCTRI/2023/07/055481Soni Yesha